

SLC27A2 antibody - N-terminal region

Rabbit Polyclonal Antibody Catalog # AI12335

Product Information

Application WB, IHC Primary Accession 014975

Other Accession NM 003645, NP 003636

ReactivityHuman, Mouse, Rat, Rabbit, Pig, Dog, Guinea Pig, Horse, Bovine **Predicted**Human, Mouse, Rat, Rabbit, Pig, Dog, Guinea Pig, Horse, Bovine

Host Rabbit
Clonality Polyclonal
Calculated MW 70312

Additional Information

Gene ID 11001

Alias Symbol ACSVL1, FACVL1, FATP2, HsT17226, VLACS, VLCS, hFACVL1

Other Names Very long-chain acyl-CoA synthetase, VLACS, VLCS, 6.2.1.-, Fatty acid transport

protein 2, FATP-2, Fatty-acid-coenzyme A ligase, very long-chain 1,

Long-chain-fatty-acid--CoA ligase, 6.2.1.3, Solute carrier family 27 member 2, THCA-CoA ligase, Very long-chain-fatty-acid-CoA ligase, SLC27A2, ACSVL1,

FACVL1, FATP2, VLACS

Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium

azide and 2% sucrose.

Reconstitution & Storage Add 50 ul of distilled water. Final anti-SLC27A2 antibody concentration is 1

mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at

20°C. Avoid repeat freeze-thaw cycles.

Precautions SLC27A2 antibody - N-terminal region is for research use only and not for use

in diagnostic or therapeutic procedures.

Protein Information

Name SLC27A2

Synonyms ACSVL1, FACVL1, FATP2, VLACS

Function Mediates the import of long-chain fatty acids (LCFA) into the cell by

facilitating their transport across cell membranes, playing an important role

in hepatic fatty acid uptake (PubMed: 10198260, PubMed: 10749848,

PubMed: 11980911, PubMed: 20530735, PubMed: 22022213,

PubMed: 24269233). Also functions as an acyl-CoA ligase catalyzing the

ATP-dependent formation of fatty acyl-CoA using LCFA and very-long- chain fatty acids (VLCFA) as substrates, which prevents fatty acid efflux from cells and might drive more fatty acid uptake (PubMed:10198260, PubMed:10749848, PubMed:11980911, PubMed:20530735, PubMed:22022213, PubMed:24269233). Plays a pivotal role in regulating available LCFA substrates from exogenous sources in tissues undergoing high levels of beta-oxidation or triglyceride synthesis (PubMed:20530735). Can also activate branched-chain fatty acids such as phytanic acid and pristanic acid (PubMed:10198260). May contribute to the synthesis of sphingosine-1-phosphate (PubMed:24269233). Does not activate C24 bile acids, cholate and chenodeoxycholate (PubMed:11980911). In vitro, activates 3-alpha,7-alpha,12-alpha- trihydroxy-5-beta-cholestanate (THCA), the C27 precursor of cholic acid deriving from the de novo synthesis from cholesterol (PubMed:11980911). However, it is not critical for THCA activation and bile synthesis in vivo (PubMed:20530735).

Cellular Location

Endoplasmic reticulum membrane; Multi-pass membrane protein. Peroxisome membrane; Peripheral membrane protein. Cell membrane; Multi-pass membrane protein. Microsome


Tissue Location

[Isoform 1]: Expressed in liver, kidney, placenta, intestine, brain, heart, and colon (PubMed:10198260, PubMed:21768100, PubMed:24269233). Predominantly expressed in liver (PubMed:20530735)


References

Mihalik, S.J., (2002) J. Biol. Chem. 277(27), 24771-24779 Reconstitution and Storage: For short termuse, store at 2-8 Cup to 1 week. For long terms to rage, store at 2-20 Cinsmall aliquots to prevent freeze-thaw cycles.

Images




Liver, Human: Formalin-Fixed, Paraffin-Embedded (FFPE)



Liver, Human: Formalin-Fixed, Paraffin-Embedded (FFPE)

Host: Rabbit

Target Name:SLC27A2



Sample Tissue:Hela Lane A: Primary Antibody Lane B: Primary Antibody + Blocking Peptide Primary Antibody Concentration:1µg/ml Peptide Concentration: 5.0 µg/ml Lysate Quantity: 25ug/lane/lane Gel

Concentration: 12%SLC27A2 is strongly supported by BioGPS gene expression data to be expressed in Human

HeLa cells

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.